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Previous studies indicate that B-lymphocytes play a key role activating diabetogenic
T-lymphocytes during the development of autoimmune diabetes. Recently, two
transgenic NOD mouse models were generated: the NOD-PerIg and the 116C-NOD
mice. In NOD-PerIg mice, B-lymphocytes acquire an activated proliferative phenotype
and support accelerated autoimmune diabetes development. In contrast, in 116C-NOD
mice, B-lymphocytes display an anergic-like phenotype delaying autoimmune diabetes
onset and decreasing disease incidence. The present study further evaluates the
T- and B-lymphocyte phenotype in both models. In islet-infiltrating B-lymphocytes
(IIBLs) from 116C-NOD mice, the expression of H2-Kd and H2-Ag7 is decreased,
whereas that of BAFF, BAFF-R, and TACI is increased. In contrast, IIBLs from
NOD-PerIg show an increase in CD86 and FAS expression. In addition, islet-infiltrating
T-lymphocytes (IITLs) from NOD-PerIg mice exhibit an increase in PD-1 expression.
Moreover, proliferation assays indicate a high capacity of B-lymphocytes fromNOD-PerIg
mice to secrete high amounts of cytokines and induce T-lymphocyte activation
compared to 116C B-lymphocytes. This functional variability between 116C and PerIg
B-lymphocytes ultimately results in differences in the ability to shape T-lymphocyte
phenotype. These results support the role of B-lymphocytes as key regulators of
T-lymphocytes in autoimmune diabetes and provide essential information on the
phenotypic characteristics of the T- and B-lymphocytes involved in the autoimmune
response in autoimmune diabetes.
Keywords: type 1 diabetes, NOD mouse, transgenic mouse model, B-lymphocyte phernotype, T-lymphocyte
phernotype
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INTRODUCTION
CD4+ and CD8+ T-lymphocytes are considered to be the
major effectors of ß-cell damage during the development
of autoimmune diabetes in both NOD mice and humans.
However, T-lymphocytes require the intervention of antigen
presenting cells (APCs), such as B-lymphocytes, which drive
and modulate their response. The involvement of B-lymphocytes
in autoimmune diabetes development was proved when disease
protection was observed in NOD mice after introducing
the Igµnull mutation or after anti-B lymphocyte antibody
treatments (1–8). Further studies indicated that B-lymphocytes
promote autoimmune diabetes development through their
APC function activating ß-cell-reactive cytotoxic T-lymphocytes
(CTLs) (9, 10). In parallel to this diabetogenic role, a protective
effect of some B-lymphocytes on autoimmunity through a
potential regulator/suppressor mechanism has been described.
Adoptive transfer of LPS-activated splenic B-lymphocytes
protects prediabetic NOD female mice from disease development
by triggering the apoptosis of ß-cell-reactive CTLs or/and
inhibiting APC activity (11).
Two transgenic NOD mouse models, the 116C-NOD and
the NOD-PerIg mice (12, 13), have been recently generated
to analyze the natural B-lymphocyte immune response during
autoimmune diabetes development. On the one hand, the
116C-NOD mouse model expresses the Ig genes from an
islet-infiltrating B lymphocyte of a diabetes resistant but
insulitis prone (8.3-NODxNOR)F1 mouse with pancreatic
islet ß-cell specificity (14). Autoimmune diabetes incidence
is decreased in 116C-NOD mice compared to NOD mice
(Supplementary Figure 1). B-lymphocytes from 116C-NOD
mice display an anergic-like phenotype but retain the ability
to express some co-stimulatory molecules after activation and
induce a T cell shift toward a Th17 phenotype. On the other hand,
the NOD-PerIg mouse expresses a representative Ig of a large
proportion of naturally occurring islet-infiltrating B-lymphocytes
in NOD mice recognizing the neuronal antigen peripherin
(14, 15). In contrast to 116C-NOD, B-lymphocytes from NOD-
PerIg mice acquire an activated proliferative phenotype and
promote an accelerated autoimmune diabetes development
(Supplementary Figure 1). Despite the differences observed
in autoimmune diabetes development, B-lymphocytes from
116C-NOD and NOD-PerIg still share certain phenotypic and
functional similarities, such as an enlargement of the marginal
zone B-lymphocyte subset, and stimulation-induced cytokine
production. Thus, the present study aims at studying in depth
the functional and phenotypic differences between T- and B-
lymphocytes in both mouse models, to better understand the
mechanisms underlying the function of both cell populations
in inhibiting or accelerating autoimmune diabetes development.
The results reveal variations in cytokine production and
expression of MHC, as well as costimulatory and inhibitory
molecules in T- and B-lymphocytes between both mouse models
that consistently result in differences in their ability to modulate
T-lymphocyte responses. The results also highlight the capacity of
B-lymphocytes to shape T-lymphocyte phenotypes and show that
T- and B-lymphocytes of both transgenic mice exert disparate
effect or functions, thus indicating why the development of the
disease in both mice models is so different.
MATERIALS AND METHODS
Mice
NOD, NOD-PerIg, and 116C-NOD mice were maintained by
brother-sister mating under specific pathogen-free conditions
at the University of Lleida. This study was carried out in
accordance with the principles of the Basel Declaration and
recommendations of the Catalan Government (Generalitat
de Catalunya) concerning the protection of animals for
experimentation. The protocol was approved by the Committee
on the Ethics of Research in Animal Experimentation of the
University of Lleida, Spain. Protocol #: CEEA 02-04/16.
Diabetes Incidence
Mice were checked weekly for glycosuria with Glucocard strips
(Meranini, Barcelona, Spain). After two positive readings (>3+)
and with a confirmation of glucose levels on blood (higher values
than 250 mg/dL), mice were considered diabetic.
Flow Cytometry
Splenocytes and islet-infiltrating leukocytes from 6-week-
old female NOD, 116C-NOD and NOD-PerIg mice were
obtained as described elsewhere (16) and then analyzed by
flow cytometry using FACS CANTO II instrumentation (BD,
Biosciences, San Jose, CA) and Flowjo (version 8.7) software
[see also Supplementary Figure 2 for histogram analysis for
fluorescence minus one (FMO) control of each staining and
for a representative analysis of transcription factor expression
in CD4+ T lymphocytes]. CD19-V450 (75-0193-U100) was
obtained from Tonbo Biosciences (San Diego, CA). CD3-
FITC (561798), CD40-Biotin (553789), CD8-Biotin (553033),
CD4-PerCp (553052), CD279-APC (562584), CD274-PacificBlue
(564715), CD86-PE (561963), CD80-Biotin (09602D), I-Ak-
Biotin (553539) which cross-reacts with I-Ag7, H-2Kd-Biotin
(553564), Fc(CD16/CD32)-PeCy7 (560829), and streptavidin-
amCyan (563261) were purchased from BD Biosciences (San
Jose, CA). Fas-APC (152603) was supplied by Biolegend (San
Diego, CA). TACI-Biotin (ABIN1169259) and BAFF-R-Biotin
(ABIN1169050) were purchased from Antibodies-online.com
(USA). BAFF-APC (130-111-029) was obtained from Miltenyi
Biotec (Madrid, Spain). For transcription factors and APRIL
intracellular staining, mononuclear cells were permeabilized
following the manufacturer’s instructions of the FoxP3 Stainning
Buffer Set (00-5523-00, ebioscience) and using the following
set of MoAbs to T-bet-Pe/Cy7 (25-5825-82), RORgt-APC
(53-9966-42), FoxP3-PacificBlue (48-5773-82), GATA3-FITC
(53-9966-42), all from ebioscience (San Diego, CA), and APRIL-
APC (130-105-388) from Miltenyi Biotec (Madrid, Spain).
Proliferation Assays
Splenocytes from 6-week-old female NOD, BDC2.5-NOD,
116C-NOD, and NOD-PerIg mice were obtained mechanically
disrupting their spleens, and red cells were lysed in 0.87%
ammonium chloride solution. Spleens from BDC2.5-NOD mice
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were donated by Dr. Pau Serra from his mouse colony at
the Institut d’Investigacions Biomèdiques August Pi i Sunyer,
Barcelona, Spain. T- and B-lymphocytes were purified by
negative selection using MACS T- and B-lymphocyte isolation
reagent (130-095-130 and 130-090-862 respectively, Myletnyi
Biotec, Madrid, Spain) following the manufacturer’s instructions.
The purity of T- and B-lymphocytes was always above
90%. For B proliferation assays, previous CFSE (C34554, life
technologies) labeled B-lymphocytes were incubated in 96-well
tissue culture plates (3 × 105/well) at 37◦C in 5% CO2 in
complete culture medium using the following stimuli: 10 ug/ml
LPS (L3012-5MG, Sigma-Aldrich Inc., St. Louis, MO), or 10
ug/mL anti-CD40 (553787, BD Biosciences, clone 3/23) plus 10
U/mL rIL-4 (404-ML-010, R&D Systems, Minneapolis, MN),
or anti-IgM, affinity pure F(ab′)2 (JAC-715-006-020, Jackson
Immunoresearch, West Grove, PA). After 48 h of culture, the
phenotype of B-lymphocytes was analyzed by flow cytometry
and culture supernatants were stored at −80◦C until use.
A minimum of four animals per group was analyzed. For
T-lymphocyte proliferation assays, previous CFSE labeled T-
lymphocytes from spleens of NOD or BDC2.5-NOD mice were
co-cultured (3 × 105 cell/well) with purified B-lymphocytes
(3 × 105 cell/well) of NOD, NOD-PerIg or 116C-NOD
to check B-lymphocyte capacity to promote T-lymphocyte
proliferation. 10 ug/mL of anti-CD3 MoAb (553058, BD), or
20 ug/mL of 2.5HIP peptide (LQTLALWSRMD) synthesized
by the proteomics and protein chemistry unit of Pompeu
Fabra University (Barcelona), was also added to cultures
or anti-CD3 coated plates to boost T-lymphocyte activation.
Seventy-two hours later, cells were analyzed by flow cytometry
and culture supernatants stored at −80◦C until use. All
B- and T-lymphocyte proliferation assays were performed
in duplicate.
Cytokine Profile Analysis
Culture supernatants from proliferation assays were collected
and IL-2, IL-4, IL-6, IFN-γ, IL-10, TNF-α, and IL-17
cytokine amounts analyzed by flow cytometry using CBA
kit (560485, BD).
Statistics
PRISM Graphpad software was used for analysis. Statistics were
performed using log-rank (Mantel-Cox) and Mann-Whitney
U-tests. All mean values± SD are shown.
RESULTS
Marked Phenotype Differences Between
B-Lymphocytes From 116C-NOD and
NOD-PerIg Mice
Since B-lymphocytes play an important role in presenting ß-
cell autoantigens to autoreactive T-lymphocytes in autoimmune
diabetes, the present study first analyzed the expression of
MHC and CD80, CD86, BAFF, BAFF-R, APRIL, and TACI
costimulatory and coinhibitory molecules in spleen and islet
infiltrating B-lymphocytes (IIBLs) from 116C-NOD and NOD-
PerIg mice. MHC class I and class II expression were deeply
down-regulated in both IIBLs and splenic B cells from 116C-
NOD, whereas only MHC class II was down-regulated in
splenic B cells from NOD-PerIg mice compared to wild type
NOD mice (Figure 1). In regard to costimulatory molecules,
the percentages of IIBLs positive for CD86 and APRIL were
lower, but higher for BAFF, BAFF-R, and TACI in 116C-
NOD when compared to wild type NOD and/or NOD-PerIg
mice (Figure 1). In fact, the number of IIBLs positive for
BAFF-R and TACI was almost absent in NOD-PerIg. Since
TACI acts as an inhibitor for lymphocyte activation through
BAFF/BAFF-R interaction, these results suggest that 116C-
NOD IIBLs cannot induce activation signals for T cells. In
contrast, the high percentage of IIBLs with up-regulation of
costimulatory molecules suggests a high capacity of these cells
from NOD-PerIg mice to be potential T-lymphocyte activators.
The level and number of Fas+ IIBLs was higher in NOD-
PerIg compared to NOD and 116C-NOD mice, thus suggesting
that IIBLs from NOD-PerIg mice exhibit a high activation
status. An increased percentage of BAFF+ B-lymphocytes is
observed in the spleen of NOD-PerIg when compared to 116C-
NOD and wild type NOD mice. A number of other less
pronounced differences in the percentage or the expression
of above mentioned molecules in splenic B-lymphocytes
were also observed between mouse strains (Figure 1). The
expression of PD-1 and PD-L1 coinhibitory molecules was
then tested in IIBLs and splenic B-lymphocytes from 116C-
NOD and NOD-PerIg mice. No differences were observed in
the percentage of PD-1+ B-lymphocytes between mice. On
the contrary, the percentage of PD-L1+ in IIBLs was lower
in all three mouse models (Figure 1) suggesting low ability
of B-lymphocytes to down regulate T-lymphocyte activity in
islet pancreatic-infiltrate.
In addition to the phenotypic changes, the ability to respond
to different stimuli determines the functional capacity of B-
lymphocytes. As previously demonstrated, 116C B-lymphocytes
have a decreased ability to proliferate but can still secrete some
cytokines in response to LPS, anti-CD40 + IL-4, and anti-
BCR (13). Proliferation and cytokine secretion analysis under
the same stimuli were carried out with splenic B-lymphocytes
from NOD-PerIg, 116C-NOD, and wild type NOD mice to
compare their activation capacity. Significant differences were
observed in the proliferation assays (Figure 2A). Interestingly,
compared to 116C-NOD and wild type NOD mice, NOD-
PerIg B-lymphocyte proliferation was higher at baseline and
under anti-CD40 + IL-4 stimuli. Of note, under anti-BCR
stimulation, NOD-PerIg B-lymphocytes did not proliferate
(Figure 2A), and an increased number of dead cells was
observed in the SSC-A/FSC-H flow cytometry analysis compared
to baseline conditions (Supplementary Figure 3). Since NOD-
PerIg B-lymphocytes seem to be already highly activated just
after isolation (baseline condition), these results suggest that they
might have undergone activation-induced cell death after BCR
stimulation. Significant differences were also observed in the B-
lymphocyte cytokine production of the different mouse strains.
B-lymphocyte secretion of TNF-α to all different stimuli, IL-6
secretion after LPS and anti-CD40 + IL-4, and IL-10 secretion
after LPS stimulation was significantly higher in NOD-PerIg
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FIGURE 1 | Expression of MHC, costimulatory and coinhibitory molecules in B-lymphocyte membrane. Median fluorescent intensity (MFI) of H2Kd, I-Ag7, and FAS
expression, and percentage values of BAFF, APRIL, BAFF-R, TACI, CD86, CD80, PD-1, PD-L1, and FAS positive islet-infiltrating or splenic B-lymphocytes from
6-week-old NOD, 116C-NOD and NOD-PerIg were analyzed (N = 5 per group, with two replicates for each experimental condition). Bars show the SD of the median
of MFI or from the percentage values. Mann-Whitney U was used for analysis and statistically significant differences are shown as *P < 0.05 or **P < 0.01.
compared to 116C-NOD and wild type NOD mice (Figure 2B).
Interestingly, B-lymphocytes from NOD-PerIg mice secreted
high amounts of IL-6 and TNF-α cytokines, even without
stimulation. Despite the external supply of IL-4, almost no IL-
4 was detected in the B-lymphocyte culture wells under the
stimulus of anti-CD40 + IL-4, thus suggesting a high uptake of
this cytokine by NOD-PerIg B-lymphocytes during the culture
period compared to 116C-NOD and wild type NOD mice
(Figure 2B). Altogether, these results suggest that NOD-PerIg B-
lymphocytes display an activated phenotype and, consequently,
might be able to activate autoreactive T-lymphocytes and induce
autoimmune diabetes development more efficiently than 116C-
NOD B-lymphocytes.
Spleen and Islet Infiltrating T-Lymphocytes
From 116C-NOD and NOD-PerIg Mice Are
Phenotypically Different
Since the functional status of B-lymphocytes can decisively
impact T-lymphocyte behavior, the phenotypic characteristics
of spleen and islet-infiltrating T-lymphocytes were analyzed
in NOD, 116C-NOD, and NOD-PerIg mice. As previously
reported (12), B-lymphocytes from 116C-NOD mice induced
a shift toward a dominant T-lymphocyte Th17 differentiation,
especially through double Th1/Th17 bias compared to NOD
mice (Figure 3A). However, no significant differences were found
regarding the T helper phenotype from CD4+ T-lymphocytes
between NOD-PerIg and NODmice either in the spleen or in the
pancreatic islet infiltrates. Only a significant increase in triple T-
bet+RORγt+FoxP3+ CD4+ T-lymphocytes was detected in the
spleen of NOD-PerIg compared to NOD mice. The expression
of PD-1 and PD-L1 by splenic and islet infiltrating CD4+ and
CD8+ T-lymphocytes from NOD, 116-NOD and NOD-PerIg
mice was then analyzed (Figure 3B). A significant increase in
the expression of PD-1 was observed in CD4+ IITLs from
NOD-PerIg compared to 116C-NOD, and in CD8+ IITLs from
NOD-PerIg and 116C-NOD compared to NOD mice. These
data indicate that the CD8+ IITLs in both NOD-PerIg and
116C-NOD mice have a highly activated phenotype. However,
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FIGURE 2 | B-lymphocyte proliferation assay. (A) CFSE analysis of proliferation responses of splenic B-lymphocytes from 6-week-old female NOD, 116C-NOD and
NOD-PerIg mice (n = 4 per group, with two replicates for each experimental condition). Splenic B-lymphocytes were purified, labeled with CFSE and cultured in the
presence (narrow line) of LPS, anti-CD40 + IL-4, anti-BCR stimuli or without stimulus (bold line) for 48 h. (B) IL-4, IL-6, TNF-α, and IL-10 cytokine concentrations were
assessed in culture supernatants of purified B lymphocytes cultured in the same conditions as described above. (a) = Amount of IL-4 added to the culture media in
absence of cells. Bars show the SD of the proliferation index or from the cytokine concentration values. Mann-Whitney U was used for analysis and statistically
significant differences are shown as *P < 0.05.
a high percentage of CD4+ IITLs express PD-1 only in NOD-
PerIg, suggesting that full activation of the IILTs occurs just in
these mice.
NOD-PerIg B-Lymphocytes Induce High
CD4+ and CD8+ T-Cell Activation
A growing body of evidence indicates that B-lymphocytes
can contribute to autoimmune diabetes development by acting
as APCs activating ß-cell autoreactive T-cells (1, 4, 10, 17–20).
However, it has also been demonstrated that some B-lymphocytes
can protect from disease development by inducing ß-cell
autoreactive CTLs apoptosis or/and inhibiting APC activity
(11). Previous studies with 116C-NOD and NOD-PerIg mice
support the idea that B-lymphocytes can perform both actions
depending on their functional status (12, 13). The present
study indicates that the profound phenotypic and functional
differences between 116C-NOD and NOD-PerIg B-lymphocytes
could explain their dual role in respectively inhibiting or
promoting autoimmune diabetes development. Thus, the ability
of B-lymphocytes from 116C-NOD and NOD-PerIg to induce
distinct NOD T-cell responses was then evaluated. The ability
of 116C-NOD and NOD-PerIg B-lymphocytes to induce T-
lymphocyte proliferation was analyzed first. The results showed
that NOD-PerIg B-lymphocytes had a higher capacity than those
from 116C-NOD and NODmice to induce CD4+ T-lymphocyte
proliferation (Figure 4A). Interestingly, the percentage of PD-
1 positive CD4+ and CD8+ T-lymphocytes was significantly
higher when co-cultured with NOD-PerIg B-lymphocytes
compared to those co-cultured with B-lymphocytes from
NOD and/or 116C-NOD mice (Figure 4B), thus confirming
the T-lymphocyte activation status. Next, the expression of
BAFF, BAFF-R, APRIL, and TACI costimulatory molecules,
Frontiers in Immunology | www.frontiersin.org 5 July 2019 | Volume 10 | Article 1732
Egia-Mendikute et al. T- and B-Lymphocyte Phenotype in Autoimmune Diabetes
FIGURE 3 | Phenotype of unstimulated splenic and islet infiltrating NOD, 116C-NOD, and NOD-PerIg T-lymphocytes. (A) T-bet, RORγt, GATA3, and FoxP3
expression was assessed by flow cytometry in splenic and islet-infiltrating T-lymphocytes from 6-week-old female NOD, 116C-NOD and NOD-PerIg mice (n = 4 per
group, with two replicates for each experimental condition). “Total” and “SP” stand for the percentage of “whole positive” and “single positive” cells for the
aforementioned marker, respectively. (B) Expression of PD-1 was analyzed by flow cytometry in the spleen and islet-infiltrating T-lymphocytes from 6-week-old female
NOD, 116C-NOD and NOD-PerIg mice (n = 4 per group, with two replicates for each experimental condition). Bars show the SD of the percentage values.
Mann-Whitney U, statistically significant differences: *P < 0.05 or **P < 0.01.
and PD-1 and PD-L1 was also assessed in B-lymphocytes
after co-culture with T-cells. The results indicated that a
significant number of B-lymphocytes from NOD-PerIg, but
not from NOD or 116-NOD mice, expressed PD-L1, thus
being protected from the CTLs killing (Figure 4C). These
results indicated that NOD-PerIg B-lymphocytes display a highly
activated phenotype that promoted both CD4+ and CD8+ T-
lymphocyte activation.
B-Lymphocytes From NOD-PerIg Mice
Enforce NOD T Cells Toward a Quadruple
T-Bet+ GATA3+ RORγT+ Foxp3+
Phenotype
As previously shown, B-lymphocytes from 116C-NOD mice
induce a shift toward a dominant T-lymphocyte Th1/Th17
differentiation (12). In the present study, the capacity of B-
lymphocytes from NOD-PerIg mice to modulate and conduct
CD4T helper responses was evaluated. As in previous assays,
transcription factor expression and cytokine production by
T-lymphocytes from NOD mice after co-culture with B-
lymphocytes from NOD-PerIg, 116C-NOD or wild type NOD
mice was analyzed. Interestingly, the results indicated that B-
lymphocytes from NOD-PerIg mice led most NOD CD4+ T-
lymphocytes toward a quadruple T-Bet+ GATA3+ RORγT+
Foxp3+ phenotype (Figure 5A). Moreover, cytokine production
analysis showed that B-lymphocytes from NOD-PerIg mice
prompted NOD T-lymphocytes to secrete significant amounts
of cytokines from different T helper subsets, although with
predominance of proinflammatory and Th1 cytokines, due to
large amounts of IFN-γ secretion (Figure 5B). These results
indicate that B-lymphocytes from NOD-PerIg mice are highly
active that mainly promote Th1 responses but not exclusively,
confirming that B-lymphocytes can enforce CD4 T-lymphocytes
toward different T helper functions depending on their
phenotype and behavior.
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FIGURE 4 | Proliferation assay and molecular marker expression by NOD T-lymphocytes co-cultured with B-lymphocytes from NOD, 116C-NOD, and NOD-PerIg
mice. (A) NOD T-lymphocyte proliferation assay. Purified splenic T-lymphocytes from NOD mice were CFSE-labeled and cultured in the presence (narrow line) of
soluble anti-CD3, or plate-coated anti-CD3, and either purified NOD, 116C-NOD, or NOD-PerIg B-lymphocytes plus anti-CD3, or without stimulus (bold line) for 72 h.
Ten NOD mice were used to obtain the T-lymphocyte pool and 4 mice of each group to obtain purified B-lymphocytes. Two replicates were carried out for each
experimental condition. The proliferation of CD4+ or CD8+ T-lymphocytes was analyzed independently. (B) The expression of PD-1 and PD-L1 in CD4+ and CD8+
NOD T-lymphocytes was analyzed after co-culturing them as previously described. (C) The proportion of NOD, 116C-NOD, and NOD-PerIg B-lymphocytes
expressing BAFF, APRIL, BAFF-R, TACI, PD-1, or PD-L1 was also assessed. All B-lymphocytes were incubated alone without stimulus or in the presence of NOD
T-lymphocytes plus anti-CD3 for 72 h (n = 4 per group, with two replicates for each experimental condition). Bars show the SD of the percentage values.
Mann-Whitney U, statistically significant differences: *P < 0.05.
B-Lymphocytes From NOD-PerIg
Presenting the 2.5HIP Epitope Promote
High BDC2.5-NOD T-Lymphocyte
Activation
In the above experiments, the differences observed in T-
lymphocyte activation could be due to the ability of anti-CD3
antibody to bind to B-lymphocytes of the different mouse
strains. To shed light on this issue, Fc receptor (CD16/CD32)
expression onNOD-PerIg, NOD, and 116C-NODB-lymphocytes
was analyzed. Higher Fc expression was observed in NOD-
PerIg compared to NOD and 116C-NOD B-lymphocytes
(Figure 6A). Thus, in order to confirm that the ability of
NOD-PerIg B-lymphocytes to activate T-lymphocytes was due
to their high capacity to express co-stimulation molecules
and cytokine secretion, rather than or only by the increase
in anti-CD3 binding capacity, BDC2.5-NOD T-lymphocyte
activation assays were performed. To this end, T-lymphocytes
from BDC2.5-NOD were incubated with their 2.5HIP cognate
epitope in the presence of B-lymphocytes from NOD, 116C-
NOD, and NOD-PerIg mice. Although the proliferation of
T-lymphocytes was not as high as expected, NOD-PerIg B-
lymphocytes were able to induce more efficiently CD4 T-
lymphocyte proliferation than their counterparts (Figure 6B).
Although no differences in the transcription factor expression
were detected (Figure 6C), BDC2.5-NOD T-lymphocytes co-
cultured with NOD-PerIg produced larger amounts of cytokines
than with NOD or 116C-NOD B-lymphocytes (Figure 6D). In
fact, BDC2.5-NOD T-lymphocytes produced larger amounts
of different cytokines distinctive of different T-lymphocyte
subsets. Surprisingly, BDC2.5-NOD T-lymphocytes incubated
with 116C-NOD proliferate as efficiently as when they were
in the presence of B-lymphocytes from NOD. These results
Frontiers in Immunology | www.frontiersin.org 7 July 2019 | Volume 10 | Article 1732
Egia-Mendikute et al. T- and B-Lymphocyte Phenotype in Autoimmune Diabetes
FIGURE 5 | Phenotype analysis of NOD T-lymphocytes after culture with B-lymphocytes from NOD, 116C-NOD, and NOD-PerIg mice. (A) Transcription factors
expression analysis in splenic NOD T-lymphocytes cultured in the presence of soluble anti-CD3, or plate-coated anti-CD3, or either purified NOD, 116C-NOD, or
NOD-PerIg B-lymphocytes plus anti-CD3, or without stimulus for 72 h (n = 6, with two replicates for each experimental condition). “Total” and “SP” stand for the
percentage of “whole positive” and “single positive” cells for the aforementioned marker, respectively. (B) Cytokine concentration analysis in culture supernatants of
NOD T-lymphocytes cultured in the same condition as described above. Bars show the SD of the percentage values or cytokine concentrations (n = 4, with two
replicates for each experimental condition). Mann-Whitney U, statistically significant differences: *P < 0.05 or **P < 0.01.
suggest the ability of 116C-NOD B-lymphocytes to overcome
their “anergic” state in order to stimulate T-lymphocytes in the
presence of an autoantigen. Nevertheless, their ability to induce
cytokine production was not as good as the one of NOD or
NOD-PerIg B-lymphocytes.
DISCUSSION
It is currently well accepted that B-lymphocytes contribute
to the development of autoimmune diabetes. The lack of
B-lymphocytes in NOD mice prevents disease development
(1–8), whereas depending on their antigenic specificity the
transgenic expression of BCRs either induces, delays, or prevents
autoimmune diabetes (10, 12, 13, 21–24). The diabetogenic
capacity of B-lymphocytes in two BCR transgenic mice, the
NOD-PerIg and the 116C-NOD strains (12, 13) was analyzed
in previous studies. In 116C-NOD mice, B-lymphocytes display
an anergic-like phenotype delaying autoimmune diabetes onset
and decreasing disease incidence, whereas in NOD-PerIg mice,
B-lymphocytes acquire an activated proliferative phenotype that
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FIGURE 6 | Analysis of BDC2.5-NOD T-lymphocyte activation after co-culture with B-lymphocytes from NOD, 116C-NOD, and NOD-PerIg mice. (A) The expression
of Fc Receptors (CD16/CD32) from B-lymphocytes was analyzed by flow cytometry before culture (n = 4 per group). (B) BDC2.5-NOD T-lymphocyte proliferation
assay. Purified splenic T-lymphocytes from BDC2.5-NOD mice were CFSE-labeled and cultured in the presence of 2.5HIP alone and with purified NOD, 116C-NOD,
or NOD-PerIg B-lymphocytes, or without stimulus for 72 h. (C) Transcription factor expression was analyzed after culturing cells as mentioned above. “Total” and “SP”
stand for the percentage of “whole positive” and “single positive” cells for the aforementioned marker, respectively. (D) Cytokine release was checked in supernatants
after 72 h. Bars show the SD of the percentage values or cytokine concentrations. In all experiments N = 4. Mann-Whitney U, statistically significant differences:
*P < 0.05.
promotes disease development. Moreover, a T helper response
imbalance toward a Th17 phenotype was observed in 116C-
NOD compared to NOD mice, thus suggesting a strong linkage
between B-lymphocyte phenotype and T-lymphocyte response.
By comparing the phenotype of the three mouse strains,
the NOD, the 116C-NOD, and the NOD-PerIg, the present
study sought to determine the most relevant B-lymphocyte
traits during autoimmune diabetes. To this end, the linkage
between phenotypic characteristics of B-lymphocytes and the
ability of these cells to induce phenotypic and functional
changes in T-lymphocytes was further analyzed. To this end,
the expression of accessory molecules and cytokine secretion
in B-lymphocytes from NOD-PerIg, 116C-NOD, and NOD
mice was evaluated. Then, through a nonspecific anti-CD3
stimulus that mimics a signal through the TCR, the ability
of these B-lymphocytes to induce T-lymphocyte activation was
also analyzed. With this approach, the effect was assessed
independently from their antigenic specificity of expressed
accessorymolecules and secreted cytokines by the B-lymphocytes
in the activation of the T-lymphocytes. Finally, B lymphocyte
capacity to act as APCs in autoimmune diabetes environment
was tested by analyzing the ability of these cells to present
a known diabetes-related autoantigen, known as 2.5HIP, a
Hybrid Insulin Peptide. In contrast to those from the NOD
and 116C-NOD strains, B-lymphocytes from NOD-PerIg mice
display an activated phenotype, secrete high amounts of
proinflammatory cytokines (even without any B-lymphocyte
stimulation), and induce significant T-lymphocyte activation. In
addition, B-lymphocytes from116C-NOD express significantly
lower levels of MHC molecules compared to those from
NOD and NOD-PerIg mice, thus indicating their inability to
perform a good antigen presentation. Although a previous study
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showed that CD86 expression levels in B-lymphocytes from
116C-NOD mice were high (12) suggesting perhaps a greater
capacity for activation of T-lymphocytes, the percentage of B-
lymphocytes expressing CD86 is lower in 116C-NOD than
in NOD and NOD-PerIg mice. Moreover, since BAFF-R and
TACI is higher in 116C-NOD than in NOD and NOD-PerIg
mice and taking into account that TACI acts as an inhibitor
for lymphocyte activation through BAFF/BAFF-R interaction,
these results suggest that 116C-NOD IIBLs cannot induce a
strong T-lymphocyte activation. In fact, current and previous
data (12) suggest that 116C-NOD B-lymphocytes would show a
greater tendency to fostering a response toward Th17 phenotype.
In contrast to the 116C-NOD B-lymphocytes, the expression
levels of MHC molecules in B-lymphocytes from NOD-PerIg
mice are similar to those from NOD mice. In addition, the
percentage of B-lymphocytes expressing high levels of the CD86
molecule and low levels of TACI and BAFF-R is higher in
NOD-PerIg mice compared to NOD and 116C-NOD mice,
indicating the strong ability of B lymphocytes to activate T
lymphocytes. Consistent with these results and those obtained
in the analysis of the incidence of autoimmune diabetes, this
study also shows that the NOD-PerIg B-lymphocytes have the
capacity to proliferate and secrete proinflammatory cytokines,
even in the absence of any stimulus, and induce a strong T-
lymphocyte proliferation. Moreover, the results also indicate
that NOD-PerIg B-lymphocytes induce CD4+ T-lymphocytes
to differentiate toward a quadruple Bet+ GATA3+ RORγT+
Foxp3+ phenotype and to secrete cytokines characteristic from
most different T helper subsets, although with predominance
of proinflammatory and Th1 cytokines, thus contributing to
autoimmune diabetes development (25). These findings were
confirmed when we analyzed the ability of the different
B-lymphocytes to induce specific responses to the known
diabetes-related peptide 2.5HIP. Even without a polyclonal
stimulus, NOD-PerIg B-lymphocytes were able to activate
specific responses from BDC2.5-NOD T-lymphocytes, inducing
a higher production of different cytokines when compared to
the other two strains. On the contrary, no changes were found
between strains in the phenotype of BDC2.5-NOD CD4+ T-
lymphocytes after stimulation with the 2.5HIP cognate epitope.
This could be due to their transgenic nature, being their prefixed
phenotype strong enough to support any input, compared to
NOD CD4+ T-lymphocytes. As observed in previous works
carried out with the transgenic model 125tg-NOD (20), our
results indicate that 116C-NOD B-lymphocytes can induce T-
lymphocyte activation and cytokine production in very specific
situations despite their “anergic phenotype.”
Thus, this study also clearly shows that depending on
their phenotype and behavior (secreted cytokine and accessory
molecule expression), B-lymphocytes from NOD, 116C-NOD,
and NOD-PerIg mice can promote CD4+ T lymphocytes
toward different T helper functions. The present findings also
illustrate that to face any insult, the immune system can bring
a combined T helper response exerted by several CD4+ T-
lymphocyte populations if required. Moreover, since the immune
system has an enormous plasticity and redundancy, other CD4+
T-lymphocytes populations of T helper that are phenotypically
double, triple or even quadruple Th positive may also be found
(26). For instance, CD4+ T-lymphocytes that are at the same
time Th1 and Th17, or other multiple possible combinations,
even some that simultaneously display multiple Th type markers.
A cell population can also pass from one phenotype to another in
the presence of certain cytokines. For example, a subpopulation
of Th9 can be differentiated from Th2 in the presence of
TGF-β (27).
In summary, this study highlights the existing
interdependence between B- and T-lymphocytes, which
gives to the former populations the chance to set up T-
lymphocyte phenotypes through the secretion of cytokines and
the expression of costimulatory and co-inhibitory molecules.
In terms of autoimmune diabetes, this study also confirms that
the most harmful response for disease development comes
from a concomitant Th1/proinflammatory response, and
that B-lymphocytes play the key role in the establishment of
this response.
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